Gastroenterology最新文献

{"title":"Prevalence of Pediatric Inflammatory Bowel Disease in the United States: Pooled Estimates from Three Administrative Claims Data Sources","authors":"Michael D. Kappelman, Colleen Brensinger, Lauren E. Parlett, Andres Hurtado-Lorenzo, James D. Lewis","doi":"10.1053/j.gastro.2024.11.004","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.004","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research","authors":"Federica Di Vincenzo, Maria A. Quintero, Payton Mendygral, Maria T. Abreu","doi":"10.1053/j.gastro.2024.08.010","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.08.010","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"173 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spotlight: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis","authors":"Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, John P. Haydek, Manasi Agrawal, Frank I. Scott, Ashwin N. Ananthakrishnan","doi":"10.1053/s0016-5085(24)05604-x","DOIUrl":"https://doi.org/10.1053/s0016-5085(24)05604-x","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"18 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elsewhere in The AGA Journals (Preview Section)","authors":"","doi":"10.1053/s0016-5085(24)05602-6","DOIUrl":"https://doi.org/10.1053/s0016-5085(24)05602-6","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"13 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CME Exam 1: An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk","authors":"","doi":"10.1053/j.gastro.2024.09.026","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.09.026","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>CME/MOC Credits</h2>The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The AGA Institute designates this journal-based CME activity for a maximum of <em>1.0 AMA PRA Category 1 Credit(s)^TM</em>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant</section></section><section><section><h2>Financial Relationship Disclosures</h2>In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Integrity and Independence in Continuing Education, all faculty and planning partners must disclose all financial relationship(s) or other relationship(s) with ineligible companies held within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AGA Institute implements a</section></section><section><section><h2>Instructions</h2>Category 1 credit can be earned by reading the relevant articles and taking these CME examinations online at <span><span>https://www.gastrojournal.org/cme/home</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>. Answers can be obtained online after completing the exam(s).</section></section><section><section><h2>Objective</h2>See articles for specific learning objective.</section></section><section><section><h2>CME Exam 1: An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk</h2><em>Wang K and Song M, Authors</em><em>Test ID No.:</em> gastro00496<em>Contact hours:</em> 1.0<em>Expiration Date:</em> December 31, 2025</section></section>","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"55 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Liang et al","authors":"Alice Boilève, Michel Ducreux, Fanny Jaulin","doi":"10.1053/j.gastro.2024.11.005","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.005","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"99 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxic and acidic tumor microenvironment-driven AVL9 promotes chemoresistance of pancreatic ductal adenocarcinoma via the AVL9-IκBα-SKP1 complex","authors":"Jinsheng Ding, Yongjie Xie, Ziyun Liu, Zhaoyu Zhang, Bo Ni, Jingrui Yan, Tianxing Zhou, Jihui Hao","doi":"10.1053/j.gastro.2024.10.042","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.10.042","url":null,"abstract":"<h3>Background &amp; Aims</h3>Gemcitabine combined with albumin-paclitaxel (AG) is a crucial therapeutic option for pancreatic ductal adenocarcinoma (PDAC). However, the response to chemotherapy is relatively poor, with rapid development of resistance. The aim of this study was to explore the mechanism of resistance to AG and to develop strategies that can sensitize the AG regimen.<h3>Methods</h3>We utilized organoid models, patient-derived xenografts (PDX), and genetically engineered mouse models (GEMM) in our study. Chromatin-Immunoprecipitation (Ch-IP), double luciferase assay, Co-immunoprecipitation (Co-IP), and far-western blotting analysis were performed to investigate the mechanism. The AVL9 inhibitors were identified through protein structure analysis and molecular docking analysis, and their efficacy was verified in PDX, PDOX, and KPC models.<h3>Results</h3>Through multi-strategy screening, we identified AVL9 as a key target for AG resistance in PDAC. Its tumor-promoting effects were confirmed in our clinical cohorts. Mechanistically, HIF-1α, a hypoxia-related transcription factor, drives the expression of AVL9. AVL9 acts as a scaffold that facilitates the binding of IκBα to SKP1, leading to enhanced ubiquitination and degradation of IκBα, which further activates the NF-κB pathway. The potential AVL9-targeting inhibitor, Edotecarin, was shown to reverse AG chemo-resistance in PDAC.<h3>Conclusion</h3>AVL9 expression is driven by HIF1α in PDAC. The physical interaction of AVL9, IκBα, and SKP1 provides a novel molecular mechanism for the abnormal activation of the NF-κB pathway. Therefore, the AVL9-targeting drug Edotecarin could be a promising therapeutic strategy for sensitizing PDAC to AG.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"99 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDO-Based Drug Screening in Advanced Pancreatic Cancer: Addressing Predictive Value and Broader Clinical Implications","authors":"Chaojie Liang, Dan Shan, Zhigang Wei","doi":"10.1053/j.gastro.2024.10.045","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.10.045","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"8 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis","authors":"Siddharth Singh, Edward V. Loftus, Berkeley N. Limketkai, John P. Haydek, Manasi Agrawal, Frank I. Scott, Ashwin N. Ananthakrishnan","doi":"10.1053/j.gastro.2024.10.001","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.10.001","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC).&lt;h3&gt;Methods&lt;/h3&gt;A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations on the pharmacological management of moderate-to-severe UC.&lt;h3&gt;Results&lt;/h3&gt;The AGA guideline panel made 14 recommendations. In adult outpatients with moderate-to-severe UC, the AGA recommends the use of infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, and guselkumab, and suggests the use of adalimumab, filgotinib, and mirikizumab over no treatment. In patients who are naïve to advanced therapies, the AGA suggests using a higher-efficacy medication (eg, infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, and guselkumab) or an intermediate-efficacy medication (eg, golimumab, ustekinumab, tofacitinib, filgotinib, and mirikizumab) rather than a lower-efficacy medication (eg, adalimumab). In patients who have previously been exposed to 1 or more advanced therapies, particularly tumor necrosis factor (TNF)-α antagonists, the AGA suggests using a higher-efficacy medication (eg, tofacitinib, upadacitinib, and ustekinumab) or an intermediate-efficacy medication (eg, filgotinib, mirikizumab, risankizumab, and guselkumab) rather than a lower-efficacy medication (eg, adalimumab, vedolizumab, ozanimod, and etrasimod). In adult outpatients with moderate-to-severe UC, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests against using methotrexate monotherapy, for induction or maintenance of remission. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab, adalimumab, and golimumab in combination with an immunomodulator over corresponding monotherapy. However, the AGA makes no recommendation in favor of, or against, the use of non-TNF antagonist biologics in combination with an immunomodulator over non-TNF biologic alone. In patients with UC who are in corticosteroid-free clinical remission for at least 6 months on combination therapy of TNF antagonists and an immunomodulator, the AGA suggests against withdrawal of TNF antagonists, but makes no recommendation in favor of, or against, withdrawing immunomodulators. In adult outpatients with moderate-to-severe UC, who have failed 5-aminosalicylates, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-aminosalicylates. Finally, in adult outpatients with moderate-se","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"99 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Differential Diagnosis: Severe, Swollen Hepatocytes in a Patient with an ALT above 1000 U/L","authors":"Michael Eller, Lindsey Westbrook, Avash Kalra","doi":"10.1053/j.gastro.2024.10.044","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.10.044","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"247 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142642660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}